{"entity":{"id":"pasireotide","kind":"drug","name":"Pasireotide","aka":["SOM230"],"tldr":"Pasireotide is a second-generation somatostatin analogue that hits more receptor types than octreotide. It is approved for Cushing's disease and acromegaly caused by pituitary tumours when surgery has not cured them, at the cost of frequent high blood sugar.","summary":"Pasireotide (SOM230) was developed by Novartis and is now marketed by Recordati. The FDA approved the twice-daily subcutaneous form in 2012 for Cushing's disease when surgery is not an option or has failed, the first drug approved for that indication, and the monthly long-acting depot in 2014 for acromegaly inadequately controlled by surgery. It normalises cortisol in a minority and growth hormone and IGF-1 in a larger fraction of patients, and shrinks tumours in many.\n\nHyperglycaemia, from suppression of insulin and incretins, is the main side effect and often needs treatment. Beyond the pituitary, the phase 2 LUNA trial tested it alone and with everolimus in lung and thymic neuroendocrine tumours and found activity in each arm, without a placebo comparison. The pituitary tumours and lung neuroendocrine tumour pages name it.","status":"approved","asOf":"2026-09-17","wikipedia":"https://en.wikipedia.org/wiki/Pasireotide","links":[{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Pasireotide"}],"tags":["subtype-drugs-wave"],"related":["octreotide-lanreotide","everolimus"],"cancers":["pituitary-tumours","lung-net"],"sections":[],"technologies":[],"targets":["sstr2"],"drugs":[],"companies":["recordati"],"institutions":[],"pathways":[],"terms":[],"trials":["nct00600886","nct01137682","nct00434148"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Signifor / Signifor LAR","modality":"Multireceptor somatostatin analogue (subcutaneous or monthly depot)","mechanism":"Binds somatostatin receptors 1, 2, 3 and 5, with far higher affinity for SSTR5 than octreotide; SSTR5 dominates on corticotroph adenomas, so it suppresses ACTH in Cushing's disease and growth hormone in acromegaly resistant to first-generation analogues.","approvals":[{"region":"US","year":2012,"indication":"Cushing's disease when pituitary surgery is not an option or has not been curative"},{"region":"US","year":2014,"indication":"Acromegaly inadequately controlled by surgery or for whom surgery is not an option (long-acting depot)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/pasireotide/","neighbours":{"drug":[{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/"},{"id":"pegvisomant","kind":"drug","name":"Pegvisomant","route":"/drugs/pegvisomant/"},{"id":"octreotide-lanreotide","kind":"drug","name":"Somatostatin analogues (octreotide, lanreotide)","route":"/drugs/octreotide-lanreotide/"}],"cancer":[{"id":"corticotroph-pitnet","kind":"cancer","name":"Corticotroph pituitary neuroendocrine tumour (Cushing disease and silent corticotroph tumour)","route":"/cancers/corticotroph-pitnet/"},{"id":"lung-net","kind":"cancer","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/cancers/lung-net/"},{"id":"pituitary-tumours","kind":"cancer","name":"Pituitary tumours (pituitary neuroendocrine tumours) and pituitary carcinoma","route":"/cancers/pituitary-tumours/"},{"id":"somatotroph-pitnet","kind":"cancer","name":"Somatotroph pituitary neuroendocrine tumour (acromegaly)","route":"/cancers/somatotroph-pitnet/"},{"id":"thyrotroph-pitnet","kind":"cancer","name":"Thyrotroph pituitary neuroendocrine tumour (TSH-secreting)","route":"/cancers/thyrotroph-pitnet/"}],"target":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/"},{"id":"sstr5","kind":"target","name":"SSTR5","route":"/targets/sstr5/"}],"company":[{"id":"recordati","kind":"company","name":"Recordati","route":"/companies/recordati/"}],"trial":[{"id":"nct01137682","kind":"trial","name":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","route":"/trials/nct01137682/"},{"id":"nct00434148","kind":"trial","name":"Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease","route":"/trials/nct00434148/"},{"id":"nct00600886","kind":"trial","name":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","route":"/trials/nct00600886/"}]}}